Abstract
This article studies the changing of concentration of vascular endothelial growth factor (VEGF) from the aqueous humor sample, before and after intravitreal injection of Bevacizumab, for treatment of complicated proliferative diabetic retinopathy (PDR) and the correlation with clinical features. This study was implemented with prospective and interventional case series; 1.25 mg of Bevacizumab was injected into the vitreous cavity to treat PDRin 48 eyes of 29 patients. Aqueous humor samples were obtained before intravitreal injection of Bevacizumab and one week after. Study results showed: VEGF concentration decreased from 474.23±361.32 pg/ml to 16.96±18.11 pg/ml (p=0.000) at all eyes after one-week injection. There were no differences in levels of VEGF among groups according to the vitreous haemorrhage, tractional retinal detachment, and retinal fibrosis. Therefore, the study exhibited a better understanding of the role of anti-VEGF in the adjuvant treatment of complicated PDR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
